Skip to main content

Table.2 Comparison of baseline parameters of patients with ICANS and patients without

From: Neurological management and work-up of neurotoxicity associated with CAR T cell therapy

  ICANS (N = 4) No ICANS (N = 11) p-value
Age (mean ± SD) 63 ± 10.3 54 ± 14.5 0.22
CSF cell count (mean ± SD) 1.8 ± 2.1 0.89 ± 0.74 0.65
Blood/CSF barrier disturbance 1/3 1/7 0.64
MRI vascular lesions (number) 2/4 3/11 0.51
Vascular comorbidities (number) 1.25 ± 0.96 1.0 ± 1.56 0.72
Thrombocytes prior to CAR T therapy (/µl) 142,000 ± 137,117 68,545 ± 44,408 0.37
LDH prior to CAR T therapy (U/l) 573 ± 566 333 ± 167 0.46
  1. Data presented as means ± SD. CRS: cytokine release syndrome; CSF: cerebrospinal fluid; ICANS: immune effector cell associated neurotoxicity syndrome; LDH: lactate dehydrogenase; MRI: magnetic resonance imaging; Student's two-tailed t test was used to calculate the p-values